Tag: ALCANZA
FDA Approves Label Expansion for Brentuximab Vedotin
The approval of brentuximab vedotin (Adcetris®; Seattle Genetics) for the treatment of adult patients with primary cutaneous anaplastic Large cell lymphoma or pcALC, which...
U.S. FDA Grants Priority Review for Brentuximab Vedotin in Cutaneous T-Cell...
The United States Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (BLA) based on data from the Phase...
Seattle Genetics Submits Supplemental Biologics License Application Brentuximab Vedotin in Cutaneous...
Seattle Genetics has submitted a supplemental Biologics License Application or BLA to the U.S. Food and Drug Administration (FDA) for brentuximab vedotin (Adcetris®) for...
ASH 2016: Informative and Clinical Useful
Each year, ahead of key annual medical society meetings we ask the same question: What to expect during the upcoming meeting. Are we going...
Alcanza Trial Demonstrates Highly Statistically Significant Improvement in Rate of Objective...
Results of the phase III Alcanza trial evaluating brentuximab vedotin (Adcetris®; Takeda Pharmaceutical and Seattle Genetics) in patients with cutaneous T-cell lymphoma (CTCL) shows...
Seattle Genetics Completes Enrollment for Phase III Trial Designed to Evaluate...
Seattle Genetics and its collaborator, Takeda Pharmaceutical, have completed patient enrollment in the open label, phase III ALCANZA (NCT01578499) clinical trial. This randomized trial is...
